Tesamorelin (20mg)

Tesamorelin (CAS 218949-48-9, MW ~5135 Da) is a synthetic GHRH analogue — the full 44-amino acid sequence of endogenous GHRH with a trans-3-hexenoic acid group at the N-terminus to improve DPP-IV resistance. It stimulates pituitary GHRH receptors to produce pulsatile GH release, which in turn increases hepatic IGF-1 production. Research has focused primarily on visceral adipose tissue biology via GH-stimulated lipolysis pathways, with clinical data from lipodystrophy trials. Secondary research areas include body composition, GH/IGF-1 axis characterisation, and emerging cognitive function data. For research use only.

Tesamorelin and GLP-1 compounds operate through entirely different mechanisms. GLP-1 research agonists act on incretin (GLP-1/GIP) and, for triple agonists, glucagon receptors. Tesamorelin instead stimulates the pituitary GHRH receptor to increase growth hormone output — it does not act on GLP-1, GIP, or glucagon receptors. Its downstream activity on lipid metabolism occurs via GH-stimulated lipolysis. In research, Tesamorelin is studied for adipose-tissue biology through this GH-axis mechanism, making it a distinct tool from the GLP-1 class. Not for human consumption — for research use only.

Both Tesamorelin and CJC-1295 (no DAC) are GHRH analogues that stimulate pulsatile GH release. Key differences: Tesamorelin is the full 44-amino acid GHRH sequence with N-terminal fatty acid modification — most closely resembling endogenous GHRH in structure. CJC-1295 is a truncated 29-amino acid GHRH fragment with four amino acid substitutions. Tesamorelin is preferred when GHRH receptor fidelity to the full endogenous sequence is a research requirement. CJC-1295 is more commonly used in combination protocols with Ipamorelin. Not for human consumption — for research use only.

Reconstitution: Draw 1–2mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly down the inside wall of the Tesamorelin vial. Gently swirl until fully dissolved — do not shake or vortex. The solution should be clear and colourless. Common concentration: 1mL BAC water = 10mg/mL. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 28 days. Protect from light throughout.

Tesamorelin is legal to purchase in Australia for legitimate laboratory research purposes. It is not listed as a scheduled substance under the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not TGA-approved for human consumption, therapeutic, or veterinary use. Our Tesamorelin 10mg is independently verified at 99.1% HPLC purity with full COA documentation. Peptide Warehouse Australia dispatches nationwide from our Melbourne warehouse via Australia Post.

Peptide Warehouse Australia stocks research-grade Tesamorelin 10mg and dispatches nationwide via Australia Post with full tracking from our Melbourne warehouse. Orders placed before 12PM AEST dispatch the same business day; orders after 12PM AEST dispatch the next business day. Standard Post (2–6 business days) $8.99; Express Post (1–3 business days) $13.99. Free shipping on orders over $199 AUD. Discreet plain packaging. For dual-pathway GH secretagogue research, also see our CJC-1295 + Ipamorelin Blend.

Tesamorelin is a synthetic analogue of the complete 44-amino-acid growth-hormone-releasing hormone, stabilised with an N-terminal modification, distinguishing it from shorter GHRH fragments such as CJC-1295 (Mod GRF 1-29). The full-length structure is central to its research profile. Not for human consumption — for research use only.

Tesamorelin has been studied in clinical and preclinical research for effects on visceral adipose tissue via growth-hormone-axis stimulation. This visceral-fat research angle is its most-cited area of investigation. Findings are from research settings; the compound is supplied strictly for research and is not TGA-approved. Not for human consumption — for research use only.

As a GHRH-receptor agonist, Tesamorelin is studied for stimulating endogenous growth-hormone release and downstream IGF-1 signalling in research models, rather than supplying growth hormone directly. This axis-stimulation mechanism is a key research variable. Not for human consumption — for research use only.

Tesamorelin is a full 44-residue GHRH analogue; CJC-1295 is a shorter modified GHRH fragment; Ipamorelin acts on the separate ghrelin/GHS receptor. All three are studied in growth-hormone-axis research but through different structures and receptors, and are distinct, non-interchangeable research tools. Not for human consumption — for research use only.